This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Doing pretty well again this morning, more or less samr pattern as Friday, up and down like a yo yo.

cheers GF.

Vaccine hopes for blood cancers

Scientists are looking at treating many types of cancer with vaccines
A vaccine to help patients fend off blood cancers could be a reality in the near future.
It could even be given to healthy people who donate bone marrow to treat patients with multiple myeloma.

Scientists have been testing candidate jabs in humans and say early results are promising.

These use specially-treated material from the patient's cancer to try to encourage the body's own immune system to pick out and attack myeloma cells.

Cancer vaccine

Myeloma develops from cells within the bone marrow called plasma cells, which produce proteins called antibodies to help to fight infection.

It does not give you cancer. There is no risk to the donor.

Researcher Dr Michael Bishop

In myeloma, a single plasma cell develops faults and multiplies out of control, producing excessive amounts of a single type of antibody.

It affects approximately 3,500 people in the UK each year, and is notoriously difficult to treat.

Even with chemotherapy and a bone marrow transplant, the average patient will live for only two to four years, meaning new treatments are urgently needed.

For the last four years, researchers from the National Cancer Institute in the US have been testing a trial vaccine in myeloma patients and healthy people donating bone marrow to these patients.

Attack

Researcher Dr Michael Bishop from the NCI's campus in Bethesda, Maryland, said: "With conventional bone marrow transplants you are transferring a new, healthy immune system to the patients with myeloma, and this new immune system is capable of recognising myeloma and attacking it.

"But this can be a relatively haphazard event.

"By giving the vaccine to the donor, they can build up immunity to the cancer.

"They will have this memory, so when the transplanted bone marrow cells come into contact with myeloma they will attack it."

Past research has already shown that giving the vaccine to the patient boosts their immune system.

Dr Bishop said it was a controversial idea to vaccinate healthy donors, but that was entirely safe.

The big issue is whether it is ethically acceptable to vaccinate donors.

A spokesman from the Leukaemia Research Fund

"The protein the vaccine is based on is a byproduct of the cancer. It does not give you cancer.

"There is no risk to the donor, other than those related to any vaccine."

He said the beauty of the treatment was that it would only attack the myeloma cells and would not harm healthy cells because its target was so specific.

He said it might be possible to treat other cancers with similarly unique targets, such as some forms of lymphoma, in the same way.

"We are very pleased with initial results."

He hopes it will be available as a treatment in coming years.

A spokesman from the Leukaemia Research Fund said: "The concept is very attractive, but there are various hurdles to get over that affect both the donor and the patient.

"The big issue is whether it is ethically acceptable to vaccinate donors."

Professor Peter Johnson, of the Cancer Research UK cancer unit at Southampton General Hospital, said: "The reason we can ethically and reasonably do that is because this is a unique antigen [target] which is only present on malignant cells in the recipient marrow."






http://news.bbc.co.uk/1/hi/health/4227361.stm

Hi All
Does anybody have an idea as to where the hell this announcement has got to? I'm getting bored waiting

DB has been on holiday the last 2 weeks but is due back in the office on Tuesday...

Mitzy
Thanks for the update, lets hope he comes back with the 'best' of information.

This is begining to sound like the advfn PET board........

SW
I wouldn't know I never use that board since someone advised,

"If that would be advfn, I would not take much notice.

That site is full of rampers and idiots".

regards Loadsa

And how true that is...............

loads........ if you are going to quote me, then do it in full, thanks.

seawallwalker - 18 Mar'05 - 13:26 - 712 of 748 edit



If that would be advfn, I would not take much notice.

That site is full of rampers and idiots.

The chances are that one is being prepared, but no one on a bb would know for sure.

Lets sit on our hands again.

&

seawallwalker - 18 Mar'05 - 13:47 - 716 of 747 edit



rob advfn has its uses, and there can be some good info there, but it is as well to take any er, "insider" type talk with a hefty pinch of salt.

OOPS!
Sorry WS was it you?. He He

25 a share in 2 years......

mitzy........ I sometimes do not no whether to reach for the valium or the champagne when I read your predictions............ long may they continue mate...... by the way I have still not taken profit (in 5 X years) and am still accumulating........ profit taking???????? for the faint hearted (and the sensible)
Keep it here guys........... Rob308(nearly an f355)but if we hit mitzy's 25 a 550 Barchetta for sure

I'm still in from 6p rob so thats a 30 bagger already but theres more to come...been a holder for 5 years through thick and thin but its worth it..!

I wish i could believe that mitzy,i have a lot of confidence in your comments on MMG but are you really that confident? I know there is a lot of news flow to come out of MMG in the near future but as we all know with pharmaceuticals the results of trials are not always successful and shares can fall heavily on bad results.If you are that confident though i might just top up my rather small holding.
DB66

good stuff.......
I have said many times on this thread do not forget all of the other products undergoing r&d in the mmg lab in camb's by various companies, ALL of which mmg have a considerable interest in.

Mitzy, if you had the b*~~s to get in at 6pence fantastic, my lowest dip was at 15 pence but the red meat is still to come.
By the way I have done a little bottom feeding lately and picked up Medysis (mdy), up 13% today and worth a look.

Rob

Thanks for that info rob.....

Just hope we keep going up and up. Dont like putting targets on share prices.

cheers GF.

No news again and the sp is marked down which is no surprise ..

.

Well the management arent helping things with their silence but Im sure if it was bad news they would have had make public the news as per the FSA rules here,

Rule 9.2 of the Listing Rules in force on 4 July 2001 states that:
A company must notify the Company Announcements Office without delay of all relevant information which is not public knowledge concerning a change:
(a) in the companys financial condition;
(b) in the performance of its business; or
(c) in the companys expectation as to its performance;
which, if made public, would be likely to lead to substantial movement in the price of its listed securities.
The continuing obligations of a listed company set out in the Listing Rules are designed to promote full disclosure to the market of all relevant information on a timely basis. The FSA regards the continuing obligation requirements of Chapter 9 of the Listing Rules as a fundamental protection for shareholders. Observance of those continuing obligations is essential to the maintenance of an orderly market in securities and of confidence in the financial system. The FSA therefore takes the most serious view of listed companies which fail to comply with these requirements.
Ends.

One could argue of course that they would also have to report any good news which would lead to a substantial move in its price but I suppose they are looking upon the genvax as already priced in before the 18th.

Seems to be speculative selling this morning which one would expect in the current market envoirement. Best to hold tight I say and were only days away from the next big news. The shares could move very much higher.

cheers GF.